1Myers GL,Christenson RH,Cushman M,et al.National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines:Emerging Biomarkers for Primary Prevention of Cardiovascular Disease[J].Clinical Chemistry,2009;55:378-384.
2Nissen SE.Effect of Intensive Lipid Lowering on Progression of Coronary Atherosclerosis:Evidence for an Early Benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Trial[J].Am J Cardiol,2005;96(5):61-68.
3Ray KK,Cannon CP,McCabe CH,et al.Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes:Results From the PROVE IT-TIMI 22 Trial[J].J Am Coll Cardiol,2005;46(8):1405-1410.
4Ridker PM,Danielson E,Fonseca FA,et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J].N Engl J Med,2008;359:2195-2207.
5Ridker PM,Danielson E,Fonseca FAH,et al.Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin:a prospective study of the JUPITER trial[J].The Lancet,2009;373(9670):1175-1182.
6Heart Protection Study Collaborative Group.Lower LDL Associated with Decreases in Cardiovas cular Events Regardless of CRP Level[J].Lancet,2011;377:469-476.
7Després J P.CRP:star trekking the galaxy of risk markers[J].Lancet,2011;377(9764):441-442.
